Current uses of radiation therapy in patients with primary CNS lymphoma

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

High-dose methotrexate (HD-MTX)-based chemotherapy is the current first-line therapy for primary CNS lymphoma. Whole-brain radiotherapy (WBRT) plays an important role in the management of primary CNS lymphoma and is indicated in patients with contraindication to chemotherapy, in patients with unusual histologic subtypes as curative treatment, as complementary therapy for patients failing to achieve complete remission after systemic chemotherapy and as salvage therapy for refractory or relapsing patients when systemic chemotherapy is no longer advisable. The two major pitfalls in WBRT use are transitory efficacy and neurotoxicity with deterioration of quality of life. Accordingly, WBRT administration as consolidation therapy in complete remission patients after first-line chemotherapy is controversial. In the present review, indications of WBRT will be outlined with emphasis on consolidation therapy, treatment-related neurotoxicity and efforts aimed at reducing toxicity.

Original languageEnglish
Pages (from-to)1327-1337
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume13
Issue number11
DOIs
Publication statusPublished - 2013

Fingerprint

Lymphoma
Radiotherapy
Drug Therapy
Brain
Therapeutics
Salvage Therapy
Complementary Therapies
Methotrexate
Quality of Life

Keywords

  • extranodal lymphoma
  • neurotoxicity
  • radiotherapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Current uses of radiation therapy in patients with primary CNS lymphoma. / Citterio, Giovanni; María Ferreri, Andrés José; Reni, Michele.

In: Expert Review of Anticancer Therapy, Vol. 13, No. 11, 2013, p. 1327-1337.

Research output: Contribution to journalArticle

@article{df7ff154242840b181072aa62b1e8a9a,
title = "Current uses of radiation therapy in patients with primary CNS lymphoma",
abstract = "High-dose methotrexate (HD-MTX)-based chemotherapy is the current first-line therapy for primary CNS lymphoma. Whole-brain radiotherapy (WBRT) plays an important role in the management of primary CNS lymphoma and is indicated in patients with contraindication to chemotherapy, in patients with unusual histologic subtypes as curative treatment, as complementary therapy for patients failing to achieve complete remission after systemic chemotherapy and as salvage therapy for refractory or relapsing patients when systemic chemotherapy is no longer advisable. The two major pitfalls in WBRT use are transitory efficacy and neurotoxicity with deterioration of quality of life. Accordingly, WBRT administration as consolidation therapy in complete remission patients after first-line chemotherapy is controversial. In the present review, indications of WBRT will be outlined with emphasis on consolidation therapy, treatment-related neurotoxicity and efforts aimed at reducing toxicity.",
keywords = "extranodal lymphoma, neurotoxicity, radiotherapy",
author = "Giovanni Citterio and {Mar{\'i}a Ferreri}, {Andr{\'e}s Jos{\'e}} and Michele Reni",
year = "2013",
doi = "10.1586/14737140.2013.851007",
language = "English",
volume = "13",
pages = "1327--1337",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Current uses of radiation therapy in patients with primary CNS lymphoma

AU - Citterio, Giovanni

AU - María Ferreri, Andrés José

AU - Reni, Michele

PY - 2013

Y1 - 2013

N2 - High-dose methotrexate (HD-MTX)-based chemotherapy is the current first-line therapy for primary CNS lymphoma. Whole-brain radiotherapy (WBRT) plays an important role in the management of primary CNS lymphoma and is indicated in patients with contraindication to chemotherapy, in patients with unusual histologic subtypes as curative treatment, as complementary therapy for patients failing to achieve complete remission after systemic chemotherapy and as salvage therapy for refractory or relapsing patients when systemic chemotherapy is no longer advisable. The two major pitfalls in WBRT use are transitory efficacy and neurotoxicity with deterioration of quality of life. Accordingly, WBRT administration as consolidation therapy in complete remission patients after first-line chemotherapy is controversial. In the present review, indications of WBRT will be outlined with emphasis on consolidation therapy, treatment-related neurotoxicity and efforts aimed at reducing toxicity.

AB - High-dose methotrexate (HD-MTX)-based chemotherapy is the current first-line therapy for primary CNS lymphoma. Whole-brain radiotherapy (WBRT) plays an important role in the management of primary CNS lymphoma and is indicated in patients with contraindication to chemotherapy, in patients with unusual histologic subtypes as curative treatment, as complementary therapy for patients failing to achieve complete remission after systemic chemotherapy and as salvage therapy for refractory or relapsing patients when systemic chemotherapy is no longer advisable. The two major pitfalls in WBRT use are transitory efficacy and neurotoxicity with deterioration of quality of life. Accordingly, WBRT administration as consolidation therapy in complete remission patients after first-line chemotherapy is controversial. In the present review, indications of WBRT will be outlined with emphasis on consolidation therapy, treatment-related neurotoxicity and efforts aimed at reducing toxicity.

KW - extranodal lymphoma

KW - neurotoxicity

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84887281432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887281432&partnerID=8YFLogxK

U2 - 10.1586/14737140.2013.851007

DO - 10.1586/14737140.2013.851007

M3 - Article

VL - 13

SP - 1327

EP - 1337

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 11

ER -